ADVANCED SOLID TUMORS CANCER
Clinical trials for ADVANCED SOLID TUMORS CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED SOLID TUMORS CANCER trials appear
Sign up with your email to follow new studies for ADVANCED SOLID TUMORS CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new daily pill called NDI-219216 for people with advanced solid tumors that have not responded to standard treatments. The study will first check safety and side effects, then look at whether the drug can shrink tumors. About 134 participants w…
Matched conditions: ADVANCED SOLID TUMORS CANCER
Phase: PHASE1, PHASE2 • Sponsor: Nimbus Wadjet, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New peptide drug PQ203 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called PQ203 in about 80 adults with advanced solid tumors, including triple-negative breast cancer, that have not responded to standard treatments. The drug is given as a weekly intravenous infusion. The main goals are to check safety…
Matched conditions: ADVANCED SOLID TUMORS CANCER
Phase: PHASE1 • Sponsor: ProteinQure Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug ORB-021 enters early human testing for advanced cancers
Disease control Recruiting nowThis early-phase trial is testing whether a new drug called ORB-021 is safe and tolerable for people with advanced solid tumors who have no standard treatment options left. About 36 adults will receive the drug through an IV to find the best dose for future studies. The main goal…
Matched conditions: ADVANCED SOLID TUMORS CANCER
Phase: PHASE1 • Sponsor: Orionis Biosciences Inc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for hard-to-treat cancers: targeted combo therapy enters trials
Disease control Recruiting nowThis study tests a new drug (GFH375) combined with either cetuximab or chemotherapy in people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the combination is safe and can shrink tumors. About 126 adults who have not responded to standa…
Matched conditions: ADVANCED SOLID TUMORS CANCER
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Live biopsy study aims to predict immunotherapy response in cancer patients
Knowledge-focused Recruiting nowThis study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will res…
Matched conditions: ADVANCED SOLID TUMORS CANCER
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC